Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 1.68
VRTX's Cash to Debt is ranked higher than
58% of the 1430 Companies
in the Global Biotechnology industry.

( Industry Median: 54.60 vs. VRTX: 1.68 )
VRTX' s 10-Year Cash to Debt Range
Min: 1.15   Max: 26.61
Current: 1.68

1.15
26.61
Equity to Asset 0.46
VRTX's Equity to Asset is ranked higher than
60% of the 1081 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. VRTX: 0.46 )
VRTX' s 10-Year Equity to Asset Range
Min: 0.07   Max: 0.93
Current: 0.46

0.07
0.93
F-Score: 3
Z-Score: 11.89
M-Score: -2.47
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -119.41
VRTX's Operating margin (%) is ranked higher than
69% of the 1162 Companies
in the Global Biotechnology industry.

( Industry Median: -90.24 vs. VRTX: -119.41 )
VRTX' s 10-Year Operating margin (%) Range
Min: -602.63   Max: 8.07
Current: -119.41

-602.63
8.07
Net-margin (%) -127.25
VRTX's Net-margin (%) is ranked higher than
68% of the 1162 Companies
in the Global Biotechnology industry.

( Industry Median: -75.86 vs. VRTX: -127.25 )
VRTX' s 10-Year Net-margin (%) Range
Min: -630.27   Max: 2.1
Current: -127.25

-630.27
2.1
ROE (%) -61.64
VRTX's ROE (%) is ranked higher than
62% of the 1309 Companies
in the Global Biotechnology industry.

( Industry Median: -30.42 vs. VRTX: -61.64 )
VRTX' s 10-Year ROE (%) Range
Min: -180.27   Max: 4.58
Current: -61.64

-180.27
4.58
ROA (%) -32.46
VRTX's ROA (%) is ranked higher than
69% of the 1438 Companies
in the Global Biotechnology industry.

( Industry Median: -25.96 vs. VRTX: -32.46 )
VRTX' s 10-Year ROA (%) Range
Min: -58.14   Max: 1.51
Current: -32.46

-58.14
1.51
ROC (Joel Greenblatt) (%) -96.53
VRTX's ROC (Joel Greenblatt) (%) is ranked higher than
79% of the 1397 Companies
in the Global Biotechnology industry.

( Industry Median: -335.68 vs. VRTX: -96.53 )
VRTX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1034.2   Max: 110.77
Current: -96.53

-1034.2
110.77
Revenue Growth (3Y)(%) -28.50
VRTX's Revenue Growth (3Y)(%) is ranked higher than
64% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: 1.30 vs. VRTX: -28.50 )
VRTX' s 10-Year Revenue Growth (3Y)(%) Range
Min: -32.4   Max: 130.2
Current: -28.5

-32.4
130.2
» VRTX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

VRTX Guru Trades in Q1 2014

Steven Cohen 114,954 sh (New)
George Soros 10,000 sh (New)
Jim Simons 312,164 sh (New)
John Burbank 2,872 sh (New)
Vanguard Health Care Fund 11,628,500 sh (+5.89%)
Pioneer Investments 1,195,955 sh (-1.70%)
» More
Q2 2014

VRTX Guru Trades in Q2 2014

Paul Tudor Jones 2,178 sh (New)
Ken Fisher 6,753 sh (New)
Vanguard Health Care Fund 11,807,500 sh (+1.54%)
Steven Cohen 934,700 sh (unchged)
Jim Simons Sold Out
John Burbank Sold Out
George Soros Sold Out
Pioneer Investments 850,152 sh (-28.91%)
» More
Q3 2014

VRTX Guru Trades in Q3 2014

Stanley Druckenmiller 146,600 sh (New)
Paul Tudor Jones 7,726 sh (+254.73%)
Pioneer Investments 661,813 sh (unchged)
Vanguard Health Care Fund 11,807,500 sh (unchged)
Ken Fisher 4,593 sh (-31.99%)
Steven Cohen 443,300 sh (-52.57%)
» More
Q4 2014

VRTX Guru Trades in Q4 2014

Andreas Halvorsen 764,200 sh (New)
Stanley Druckenmiller Sold Out
Pioneer Investments 647,257 sh (-2.20%)
Ken Fisher 4,378 sh (-4.68%)
Paul Tudor Jones 6,589 sh (-14.72%)
Vanguard Health Care Fund 9,808,860 sh (-16.93%)
Steven Cohen 16,500 sh (-96.28%)
» More
» Details

Insider Trades

Latest Guru Trades with VRTX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 27.55
VRTX's Forward P/E is ranked higher than
88% of the 1590 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. VRTX: 27.55 )
N/A
P/B 28.00
VRTX's P/B is ranked lower than
62% of the 1590 Companies
in the Global Biotechnology industry.

( Industry Median: 6.80 vs. VRTX: 28.00 )
VRTX' s 10-Year P/B Range
Min: 5.79   Max: 37
Current: 28

5.79
37
P/S 50.70
VRTX's P/S is ranked higher than
50% of the 1590 Companies
in the Global Biotechnology industry.

( Industry Median: 37.92 vs. VRTX: 50.70 )
VRTX' s 10-Year P/S Range
Min: 4.47   Max: 80.48
Current: 50.7

4.47
80.48
EV-to-EBIT -44.56
VRTX's EV-to-EBIT is ranked higher than
61% of the 1590 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. VRTX: -44.56 )
VRTX' s 10-Year EV-to-EBIT Range
Min: -49.4   Max: 4164.9
Current: -44.56

-49.4
4164.9
Current Ratio 4.20
VRTX's Current Ratio is ranked higher than
72% of the 1394 Companies
in the Global Biotechnology industry.

( Industry Median: 4.44 vs. VRTX: 4.20 )
VRTX' s 10-Year Current Ratio Range
Min: 2.23   Max: 20.55
Current: 4.2

2.23
20.55
Quick Ratio 4.12
VRTX's Quick Ratio is ranked higher than
73% of the 1394 Companies
in the Global Biotechnology industry.

( Industry Median: 4.25 vs. VRTX: 4.12 )
VRTX' s 10-Year Quick Ratio Range
Min: 2.23   Max: 20.55
Current: 4.12

2.23
20.55
Days Inventory 101.73
VRTX's Days Inventory is ranked higher than
89% of the 1590 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. VRTX: 101.73 )
VRTX' s 10-Year Days Inventory Range
Min: 62.49   Max: 254.87
Current: 101.73

62.49
254.87
Days Sales Outstanding 47.77
VRTX's Days Sales Outstanding is ranked higher than
87% of the 1590 Companies
in the Global Biotechnology industry.

( Industry Median: 128.03 vs. VRTX: 47.77 )
VRTX' s 10-Year Days Sales Outstanding Range
Min: 25.75   Max: 106.15
Current: 47.77

25.75
106.15

Valuation & Return

vs
industry
vs
history
Price/Net Cash 236.00
VRTX's Price/Net Cash is ranked higher than
53% of the 1590 Companies
in the Global Biotechnology industry.

( Industry Median: 105.00 vs. VRTX: 236.00 )
VRTX' s 10-Year Price/Net Cash Range
Min: 5.43   Max: 224.15
Current: 236

5.43
224.15
Price/Net Current Asset Value 150.70
VRTX's Price/Net Current Asset Value is ranked higher than
51% of the 1590 Companies
in the Global Biotechnology industry.

( Industry Median: 41.60 vs. VRTX: 150.70 )
VRTX' s 10-Year Price/Net Current Asset Value Range
Min: 3.06   Max: 99.83
Current: 150.7

3.06
99.83
Price/Tangible Book 29.90
VRTX's Price/Tangible Book is ranked lower than
59% of the 1590 Companies
in the Global Biotechnology industry.

( Industry Median: 9.90 vs. VRTX: 29.90 )
VRTX' s 10-Year Price/Tangible Book Range
Min: 2.9   Max: 75.48
Current: 29.9

2.9
75.48
Price/Median PS Value 2.80
VRTX's Price/Median PS Value is ranked higher than
68% of the 1590 Companies
in the Global Biotechnology industry.

( Industry Median: 3.04 vs. VRTX: 2.80 )
VRTX' s 10-Year Price/Median PS Value Range
Min: 0.29   Max: 4.14
Current: 2.8

0.29
4.14
Earnings Yield (Greenblatt) -2.20
VRTX's Earnings Yield (Greenblatt) is ranked higher than
77% of the 1388 Companies
in the Global Biotechnology industry.

( Industry Median: -5.90 vs. VRTX: -2.20 )
VRTX' s 10-Year Earnings Yield (Greenblatt) Range
Min: -2.2   Max: 5.3
Current: -2.2

-2.2
5.3

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:VX1.Germany, VRTX.Mexico,
Vertex Pharmaceuticals Inc was incorporated in 1989. The Company is engaged in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases in specialty markets. It is focused on developing and commercializing therapies for the treatment of cystic fibrosis and advancing its research and early-stage development programs. The Company has marketed KALYDECO (ivacaftor) since it was approved in 2012 for the treatment of certain patients with CF and is seeking approval to market lumacaftor in combination with ivacaftor in order to increase the number of patients with CF who would be eligible for treatment with the Company's drugs. It is engaged in a number of other research and early-stage development programs, including programs in the areas of oncology and neurology. The Company's two products are INCIVE (telaprevir), which is approved for the treatment of patients with genotype 1 hepatitis C virus, or HCV, infection; and KALYDEC (ivacaftor), which is approved in the United States for the treatment of patients six years of age and older with cystic fibrosis, or CF, who genetic mutation in their cystic fibrosis transmembrane conductance regulator, or CFTR, gene, which is referred to as the G551D mutation. INCIVEK is approved in the United States and Canada for the treatment of adults with genotype 1 hepatitis C virus, or HCV, infection. As the Company markets and sells its approved products and advances its drug candidates through clinical development toward commercialization, it continues to build and maintain its supply chain and quality assurance resources. It faces competition based on the safety and efficacy of its products and drug candidates, the timing and scope of regulatory approvals, the availability and cost of supply, marketing and sales capabilities, reimbursement coverage, price, patent protection and other factors. Its registered trademarks include Vertex, KALYDECO and INCIVEK. The research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, safety monitoring, record keeping, promotion, advertising, distribution and marketing of its products and drug candidates are subject to extensive regulation by United States and foreign governmental authorities.
» More Articles for VRTX

Headlines

Articles On GuruFocus.com
J.P. Morgan Chimes In With Ratings On BioTech Stocks Jan 06 2015 
William Blair’s Top BioPharmaceutical Stock Picks for Q1 2015 Dec 23 2014 
Weekly CFO Sells Highlight: Texas Instruments Inc, Royal Caribbean Cruises Ltd, Vertex Pharmaceutica Nov 09 2014 
Weekly CFO Sells Highllight: Facebook Inc, Vertex Pharmaceuticals Inc, Nike Inc. Oct 06 2014 
Vanguard Health Care Fund Buys Vertex Pharmaceuticals, Zoetis Inc, , Sells Cerner Corporation, AbbVi Aug 02 2013 
Weekly Guru Bargains Highlights: MBI, VRTX, GRPN, PBI, PC Dec 16 2012 
WEEKLY CFO SELLS HIGHLIGHT: AKRX, FIO, OVRL, VRTX Oct 22 2012 
Idenix Pharmaceuticals Lagging Behind in Breakthrough Hepatitis C Drug Development Jul 13 2012 
Weekly Top Insider Sells: GMCR, VRTX, CERN, and AGN May 14 2012 
Vertex Could Climb On New Drug, VX-222 Success Apr 22 2012 


More From Other Websites
Biotech Investors Shouldn't Miss These Stocks This Earnings - Earnings ESP Apr 17 2015
Will a New Vertex Drug for Cystic Fibrosis Become a Budget Buster? Apr 15 2015
Growth In Drug Spend Is Hitting A 13-Year High. Note To Pharma: Innovation Pays. Apr 13 2015
Stocks Up For Second Week As GE Soars Apr 10 2015
Here are 10 local biotechs investing heavily in their future Apr 10 2015
The BBJ’s top real estate stories of the week: April 10, 2015 Apr 10 2015
Canaccord Ups Vertex To Buy On Cystic Fibrosis Drug Potential Apr 10 2015
Vertex to Announce First Quarter 2015 Financial Results on April 29 Apr 09 2015
Vertex to Announce First Quarter 2015 Financial Results on April 29 Apr 09 2015
Stock Market News for April 08, 2015 - Market News Apr 08 2015
Alnylam to move HQ to former Vertex site in big 2018 biotech shuffle Apr 06 2015
Is the FDA Worried About Vertex's New Drug? Mar 31 2015
Why Citigroup Removed Gilead Sciences From Its 'Most Preferred' List Mar 30 2015
11 promising drugs poised to be the next billion-dollar blockbusters Mar 27 2015
RBC Has 4 Biotech Stocks to Buy After Massive Pullback Mar 27 2015
The Zacks Analyst Blog Highlights: Biogen, Prothena, Vertex, Gilead and Amgen - Press Releases Mar 26 2015
One analyst is convinced the biotech stock plunge is 'misguided' Mar 26 2015
Vertex Falls on Disappointing Kalydeco+VX-661 Combo Data - Analyst Blog Mar 24 2015
Vertex Treatment May Have High Risk of Failure, Analyst Suggests Mar 24 2015
Stock Market News for March 24, 2015 - Market News Mar 24 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK